Shares in Bioglan Pharma, the British pharmaceutical company with a Dublin listing, fell almost 27 per cent on the London market yesterday after ABN-Amro resigned as broker and financial adviser to the company.

Bioglan shares were 85p lower on 240p sterling. In a statement, Bioglan said the appointment of a new broker and financial adviser is imminent and also stated that it is in negotiations to acquire a portfolio of dermatology products from a major company.